Document Detail

Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor.
MedLine Citation:
PMID:  22861371     Owner:  NLM     Status:  MEDLINE    
Mast cells are involved in the development of psoriatic lesion, but it is not known how mast cells are activated or whether mast cell cytokines are expressed during the lesion development. In this study, the Köbner reaction was induced in uninvolved psoriatic skin of 18 patients using the tape-stripping technique, and a sequence of biopsies was collected at 0 days, 2 h and 3 days or at 0 days, 1 day and 7 days for histochemical analysis. Eight patients developed the Köbner reaction verified at the follow-up visit 2-2·5 weeks later. No significant differences were observed in total tryptase(+) mast cells, psoriasis area and severity index and age/sex. Instead, the percentage of tryptase(+) mast cells showing interleukin (IL)-6 immunoreactivity was significantly higher in biopsies from Köbner-positive patients than in those from Köbner-negative patients. IL-33 is a known inducer of IL-6 in mast cells, and the number of IL-33(+) cells increased significantly in Köbner-positive dermal skin at days 3-7. The number of dermal cells with IL-6 receptor (IL-6R, CD126) also increased in Köbner-positive skin at days 3-7. Unexpectedly, the number of IL-6R(+) cells was even higher in Köbner-negative skin at days 3-7. In the chronic plaque of 10 other psoriatic patients, the numbers of IL-6(+) mast cells and dermal cells showing IL-6R were higher than those in the non-lesional skin. In conclusion, the positive Köbner reaction is associated with IL-6 in mast cells and appearance of IL-6R(+) and IL-33(+) dermal cells. This suggests that a previously unrecognized vicious circle may develop in the early psoriatic lesion.
M-M Suttle; G Nilsson; E Snellman; I T Harvima
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  169     ISSN:  1365-2249     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-06     Completed Date:  2012-10-16     Revised Date:  2013-09-03    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  311-9     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.
Department of Dermatology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Count
Dermis / metabolism,  pathology*
Epidermis / injuries,  metabolism,  pathology*
Erythema / etiology,  metabolism,  pathology
Interleukin-6 / biosynthesis*
Interleukins / biosynthesis*
Mast Cells / metabolism,  pathology*
Middle Aged
Psoriasis / metabolism,  pathology*
Random Allocation
Receptors, Interleukin-6 / biosynthesis*
Severity of Illness Index
Surgical Tape
Time Factors
Reg. No./Substance:
0/IL33 protein, human; 0/IL6 protein, human; 0/Interleukin-6; 0/Interleukins; 0/Receptors, Interleukin-6

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hepatic expression of CCL2 in alcoholic liver disease is associated with disease severity and neutro...
Next Document:  Anti-interleukin-12/23p40 antibody attenuates chronic rejection of cardiac allografts partly via inh...